Benedict Financial Advisors’s Gain Therapeutics GANX Stock Holding History

Benedict Financial Advisors’s Portfolio GANX Stock Details GANX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$71K	Buy	35,000 +19,500	+126%	+$35.9K	0.01%	142
2026 Q1	$30.1K	Sell	15,500 -22,500	-59%	-$49K	0.01%	133
2025 Q4	$122K	Buy	38,000 +3,000	+9%	+$8.01K	0.03%	134
2025 Q3	$62K	Buy	35,000 +12,500	+56%	+$21.1K	0.01%	128
2025 Q2	$40.5K	Buy	22,500 +4,500	+25%	+$8.32K	0.01%	125
2025 Q1	$34.4K	Buy	18,000 +2,000	+13%	+$4.44K	0.01%	127
2024 Q4	$34.6K	Buy	+16,000	New	+$32.1K	0.01%	123

Other funds holding GANX

OLA

Oliver Luxxe Assets Gladstone, New Jersey $680M AUM 47.51% 1-Year Est. Return

Wealth Enhancement Advisory Services Plymouth, Minnesota $59.8B AUM 29.42% 1-Year Est. Return

Benedict Financial Advisors's GANX Position: Q2 2026 in Review

Benedict Financial Advisors increased its Gain Therapeutics (GANX) stake by 126% in Q2 2026, buying an estimated $35.9K and bringing the position to 35,000 shares worth $71K. The position accounts for 0.01% of the portfolio, ranked #142.

Benedict Financial Advisors first reported a position in GANX in Q4 2024 and has held it in 7 quarters since. The position peaked at $122K in Q4 2025. 3 funds tracked by Wall St. Rank hold GANX as of Q2 2026.

Benedict Financial Advisors held 35,000 shares of Gain Therapeutics worth $71K as of Q2 2026.
Benedict Financial Advisors bought 19,500 Gain Therapeutics shares in Q2 2026, an estimated $35.9K.
Gain Therapeutics made up 0.01% of Benedict Financial Advisors's portfolio in Q2 2026, its #142 holding.
Benedict Financial Advisors first reported a position in Gain Therapeutics in Q4 2024 and has held it in 7 quarters since.
Benedict Financial Advisors's Gain Therapeutics position peaked at $122K in Q4 2025.
3 funds tracked by Wall St. Rank held Gain Therapeutics as of Q2 2026.

Based on Benedict Financial Advisors's 13F filing for Q2 2026, filed 16 Jul 2026.